The evaluation and option agreement relates to the application of the RUBY platform in specific infectious diseases.

An option fee in installments of USD 75,000 is payable to Alligator.

The agreement includes a two-year evaluation period and provides the counterparty with an exclusive option to negotiate a license agreement based on the evaluation of certain antibodies in the RUBY bispecific antibody format. An option fee in installments of USD 75,000 is payable to Alligator.

This RUBY agreement exemplifies how our innovation engine can foster innovative products and at the same time generate non-dilutive financing to support our long-term strategy.

“While our primary focus remains firmly on advancing mitazalimab into Phase 3 and securing a commercial partnership, we continue to explore opportunities to unlock additional value from our proprietary antibody platforms,” says Søren Bregenholt, CEO of Alligator Bioscience. “This RUBY agreement exemplifies how our innovation engine can foster innovative products and at the same time generate non-dilutive financing to support our long-term strategy.”